Save information for later
Sign Up

Learn About Malignant Peripheral Nerve Sheath Tumor

What is the definition of Malignant Peripheral Nerve Sheath Tumor?
A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.
What are the alternative names for Malignant Peripheral Nerve Sheath Tumor?
  • Malignant peripheral nerve sheath tumor
  • MPNST
  • Malignant neurilemmoma
  • Malignant neurofibroma
  • Malignant schwannoma
  • Neurofibrosarcoma
  • Neurogenic sarcoma
Who are the top Malignant Peripheral Nerve Sheath Tumor Local Doctors?
Elite in Malignant Peripheral Nerve Sheath Tumor
Hematology Oncology | Hematology | Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

Christine Pratilas
Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatrics | Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Pediatrics | Oncology

Johns Hopkins Children's Center

Baltimore, MD 
Languages Spoken:
English

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy.

 
 
 
 
Learn about our expert tiers
Learn More
Richard F. Riedel
Advanced in Malignant Peripheral Nerve Sheath Tumor
Advanced in Malignant Peripheral Nerve Sheath Tumor

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Richard Riedel is an Oncologist in Durham, North Carolina. Dr. Riedel is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is currently accepting new patients.

What are the latest Malignant Peripheral Nerve Sheath Tumor Clinical Trials?
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Summary: This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

Summary: The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center